Injecting REPRONEX®

At Ferring, we understand that having to mix and administer your own medication can be an intimidating procedure, so we want to make it as easy for you as possible.

REPRONEX® is approved for both subcutaneous (SC) and intramuscular (IM) injection. Whether your doctor has prescribed an SC or IM injection method, we’ve developed easy-to-follow injection guides, which can be found below. REPRONEX® is approved for reconstitution with the Q•Cap™ needle-free vial adapter. Simply access the instructions that match your doctor’s recommendation.

Subcutaneous Administration

Step-by-Step Guide

View each step of the injection process, so that you can proceed at your own pace. Or, print out the entire guide and take it with you.

Q•CAP reconstitution:
English Spanish Arabic Chinese Vietnamese Russian

Needle reconstitution:
English Spanish

View the Administration Guide Video
 


Intramuscular Administration

Step-by-Step Guide

View each step of the injection process, so that you can proceed at your own pace. Or, print out the entire guide and take it with you.

Q•CAP reconstitution:
English Spanish

Needle reconstitution:
English Spanish

View the Administration Guide Video
 

It is natural to have questions about your infertility treatment. This section of our Web site contains the practical and detailed information about REPRONEX that you need, including:

REPRONEX®, in conjunction with hCG, is indicated for multiple follicular development (controlled ovarian stimulation) and ovulation induction in patients who have previously received pituitary suppression.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe REPRONEX®. REPRONEX®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. REPRONEX® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; the presence of any cause of infertility other than anovulation unless they are candidates for in-vitro fertilization; abnormal bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins; REPRONEX® is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.

Click here to see Full Prescribing Information for REPRONEX®.


Previous:
Using REPRONEX®
Next:
REPRONEX® FAQs